Exclusion of persons with kidney disease in trials of peripheral artery disease: A systematic review of randomized trials

Yumeng Wen; O. Alison Potok; Xin Wei; Ishan Paranjpe; Lili Chan; Rakesh Malhotra; Steven Coca; Jagat Narula; Jeffrey W. Olin; Girish N. Nadkarni; Pranav S. Garimella

doi:10.2215/CJN.10330819

Exclusion of persons with kidney disease in trials of peripheral artery disease: A systematic review of randomized trials

Yumeng Wen
, O. Alison Potok
, Xin Wei
, Ishan Paranjpe
, Lili Chan
, Rakesh Malhotra
, Steven Coca
, Jagat Narula
, Jeffrey W. Olin
, Girish N. Nadkarni
, Pranav S. Garimella

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English
Pages (from-to)	117-119
Number of pages	3
Journal	Clinical Journal of the American Society of Nephrology
Volume	15
Issue number	1
DOIs	https://doi.org/10.2215/CJN.10330819
State	Published - Jan 2020

Access to Document

10.2215/CJN.10330819

Cite this

Wen, Y., Potok, O. A., Wei, X., Paranjpe, I., Chan, L., Malhotra, R., Coca, S., Narula, J., Olin, J. W., Nadkarni, G. N., & Garimella, P. S. (2020). Exclusion of persons with kidney disease in trials of peripheral artery disease: A systematic review of randomized trials. Clinical Journal of the American Society of Nephrology, 15(1), 117-119. https://doi.org/10.2215/CJN.10330819

@article{7203f54c53c34ccba2427f350eacee40,

title = "Exclusion of persons with kidney disease in trials of peripheral artery disease: A systematic review of randomized trials",

author = "Yumeng Wen and Potok, \{O. Alison\} and Xin Wei and Ishan Paranjpe and Lili Chan and Rakesh Malhotra and Steven Coca and Jagat Narula and Olin, \{Jeffrey W.\} and Nadkarni, \{Girish N.\} and Garimella, \{Pranav S.\}",

note = "Funding Information: stock options in pulseData; and owning equity and stock options in RenalytixAI. Dr. Garimella reports receiving a grant from the University of California, San Diego{\textquoteright}s Altman Clinical and Translational Research Institute, speaker fees from Otsuka Pharmaceutical and clinical trial support from Kadmon Corporation outside of the submitted work. Dr. Nadkarni reports receiving personal fees from BioVie, GLG Consulting, and Precision Xtract outside of the submitted work. Dr. Nadkarni is also the Scientific Founder of RenalytixAI and reports receiving grant funding from outside of the submitted work and holding equity in Renalytix AI. Dr. Chan, Dr. Malhotra, Dr. Narula, Dr. Olin, Dr. Paranjpe, Dr. Potok, Dr. Wei, and Dr. Wen have nothing to disclose. Funding Information: Dr. Chan is supported by a National Institutes of Health T32 grant. Dr. Garimella is supported by a grant from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; K23 DK114556). Dr. Nadkarni is supported by a grant from the NIDDK (1K23 DK107908-01A1). Dr. Potok is supported by grants from the NIDDK (T32 DK104717), Akebia Therapeutics, Inc. and the American Kidney Fund Clinical Scientist in Nephrology Fellow Program.",

year = "2020",

month = jan,

doi = "10.2215/CJN.10330819",

language = "English",

volume = "15",

pages = "117--119",

journal = "Clinical Journal of the American Society of Nephrology",

issn = "1555-9041",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

Wen, Y, Potok, OA, Wei, X, Paranjpe, I, Chan, L, Malhotra, R, Coca, S, Narula, J, Olin, JW , Nadkarni, GN & Garimella, PS 2020, 'Exclusion of persons with kidney disease in trials of peripheral artery disease: A systematic review of randomized trials', Clinical Journal of the American Society of Nephrology, vol. 15, no. 1, pp. 117-119. https://doi.org/10.2215/CJN.10330819

TY - JOUR

T1 - Exclusion of persons with kidney disease in trials of peripheral artery disease

T2 - A systematic review of randomized trials

AU - Wen, Yumeng

AU - Potok, O. Alison

AU - Wei, Xin

AU - Paranjpe, Ishan

AU - Chan, Lili

AU - Malhotra, Rakesh

AU - Coca, Steven

AU - Narula, Jagat

AU - Olin, Jeffrey W.

AU - Nadkarni, Girish N.

AU - Garimella, Pranav S.

N1 - Funding Information: stock options in pulseData; and owning equity and stock options in RenalytixAI. Dr. Garimella reports receiving a grant from the University of California, San Diego’s Altman Clinical and Translational Research Institute, speaker fees from Otsuka Pharmaceutical and clinical trial support from Kadmon Corporation outside of the submitted work. Dr. Nadkarni reports receiving personal fees from BioVie, GLG Consulting, and Precision Xtract outside of the submitted work. Dr. Nadkarni is also the Scientific Founder of RenalytixAI and reports receiving grant funding from outside of the submitted work and holding equity in Renalytix AI. Dr. Chan, Dr. Malhotra, Dr. Narula, Dr. Olin, Dr. Paranjpe, Dr. Potok, Dr. Wei, and Dr. Wen have nothing to disclose. Funding Information: Dr. Chan is supported by a National Institutes of Health T32 grant. Dr. Garimella is supported by a grant from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; K23 DK114556). Dr. Nadkarni is supported by a grant from the NIDDK (1K23 DK107908-01A1). Dr. Potok is supported by grants from the NIDDK (T32 DK104717), Akebia Therapeutics, Inc. and the American Kidney Fund Clinical Scientist in Nephrology Fellow Program.

PY - 2020/1

Y1 - 2020/1

UR - https://www.scopus.com/pages/publications/85077727240

U2 - 10.2215/CJN.10330819

DO - 10.2215/CJN.10330819

M3 - Letter

C2 - 31888921

AN - SCOPUS:85077727240

SN - 1555-9041

VL - 15

SP - 117

EP - 119

JO - Clinical Journal of the American Society of Nephrology

JF - Clinical Journal of the American Society of Nephrology

IS - 1

ER -